)
Visual
test
Medexus Pharmaceuticals
Medexus Pharmaceuticals (MDP) investor relations material
Medexus Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Nov, 2025
Executive summary
Graphopex/GRAFAPEX launch exceeded pre-launch expectations, with October 2025 marking the highest patient demand since launch in February 2025.
83% of U.S. transplant centers engaged; 29% have ordered Graphopex/GRAFAPEX, and 69% of those have reordered.
Company expects Graphopex/GRAFAPEX to be accretive to operating cash flows by fiscal Q3 2026.
Focus remains on advancing Graphopex/GRAFAPEX in the U.S. and maintaining strong performance across the product portfolio.
Financial highlights
Fiscal Q2 2026 net revenue was $24.7 million, down from $26.3 million year-over-year, with $3.1 million from Graphopex/GRAFAPEX.
Adjusted EBITDA for Q2 2026 was $4.4 million, down from $6 million year-over-year, reflecting launch investments and competition.
Gross margin improved to 55.7% for Q2, with Adjusted Gross Margin at 65.2% and product-level margin for Graphopex/GRAFAPEX at 87.8%.
Net loss of $0.3 million for Q2, compared to net income of $0.1 million last year.
Available liquidity was $9.4 million as of September 30, 2025, down from $24 million at March 31, 2025, mainly due to $16.6 million in debt repayments.
Outlook and guidance
Graphopex/GRAFAPEX expected to contribute positively to operating cash flows by fiscal Q3 2026.
Fiscal Q3 2026 Graphopex product-level net revenue guidance: $2.5 million–$3.5 million; demand sales guidance: $3 million–$4 million.
Annual product-level net revenue from Graphopex/GRAFAPEX expected to exceed $100 million within five years of launch, subject to execution.
Anticipated acceleration in Graphopex/GRAFAPEX adoption as adult reimbursement improves and NTAP program supports access.
July 2025 US tariffs on EU pharmaceutical imports will apply to Graphopex/GRAFAPEX and Rasuvo at 15%, but impact is not expected to be material.
Why is Q3 GRAFAPEX demand higher than revenue?
What is the expected impact of Otrexup's withdrawal?
Update on credit agreement refinancing progress
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Medexus Pharmaceuticals earnings date
Q3 202612 Feb, 2026
Medexus Pharmaceuticals
Next Medexus Pharmaceuticals earnings date
Q3 202612 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the specialty areas of rheumatoid arthritis, asthma/allergy, psoriasis/dermatology, and gastrointestinal disorders through its sales and marketing activities and an expanding network of professional relationships. The company markets its products through sales representatives.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage